![Advancing Patient Access to NGS for cancer in APAC](https://oncodaily.com/pub/uploads/2024/07/Pi7_Tool_1721114103519.jpg)
Photo from Roche Diagnostics Asia Pacific/LinkedIn
Jul 18, 2024, 08:37
Advancing Patient Access to NGS for cancer in APAC
Roche Diagnostics Asia Pacific posted on LinkedIn:
“Did you know that clinical outcomes for cancer in APAC have an estimated mortality-to-incidence ratio (MIR) of 0.52 as compared to 0.32 in the West?
This is why innovative technologies like Next-Generation Sequencing (NGS) are a potential game-changer in cancer care. This latest paper written by Asia Pacific Medical Technology Association (APACMed), explores NGS’s role in personalized treatment, its real-world impact on patient outcomes, and a value assessment framework to improve access. .
Read about this in the whitepaper here.”
Aug 23, 2024, 06:11